目的 为了解CRF血液透析患者EPO治疗贫血的疗效与ACEI之间的关系。方法 对透析稳定、充分,伴有贫血与高血压患者,排除了缺铁、感染、铝中毒、继发性甲旁亢后,在应用EPO的同时,观察使用与不使用ACEI两组间贫血纠正的疗效。用随机对照的方法进行前瞻性的分析。结果 用ACEI组,EPO纠正贫血的达标率(Hb≥100g/L,Hct≥30％)为20.8％,不用ACEI组为55.5％。在用ACEI组达标的5例仅用ACEI10mg/d,未达标者ACEI用量较大,其中4例>40mg/d。结论 较大剂量的ACEI对EPO纠正贫血有一定的影响。 Objective To understand the relationship between the efficacy of EPO in the treatment of anemia in CRF hemodialysis patients and ACEI. Methods After dialysis was stable and adequate, patients with anemia and hypertension were excluded, iron deficiency, infection, aluminum poisoning and secondary hyperparathyroidism were excluded. At the same time of applying EPO, anemia was corrected with or without ACEI Efficacy. A prospective analysis was performed using a randomized controlled trial. Results In ACEI group, the compliance rate of EPO for correcting anemia was 20.8% (Hb≥100g / L, Hct≥30%), and 55.5% in ACEI group. ACEI group with the standard of 5 cases only ACEI10mg / d, not enough ACEI dosage is larger, of which 4 cases> 40mg / d. Conclusions A higher dose of ACEI has a certain impact on EPO correction of anemia.